Neuphoria Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

Neuphoria Therapeutics (NEUP) filed an 8-K for a shareholder vote. Keep an eye on the outcome.

AI Summary

Neuphoria Therapeutics Inc. filed an 8-K on December 17, 2025, reporting on a submission of matters to a vote of security holders. The filing indicates that the earliest event reported was on December 12, 2025. The company is incorporated in Delaware and its principal executive offices are located at 100 Summit Dr, Burlington, Massachusetts.

Why It Matters

This filing signals a significant corporate event where security holders are being asked to vote on important company matters, which could impact the company's future direction and shareholder rights.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can introduce uncertainty and potential changes in corporate governance or strategy, which may carry medium risk.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• December 12, 2025 (date) — Earliest event reported
• December 17, 2025 (date) — Filing date
• 100 Summit Dr, Burlington, Massachusetts 01803 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — ge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq

Filing Documents

• ea0270035-8k_neuphoria.htm (8-K) — 34KB
• 0001213900-25-122777.txt ( ) — 195KB
• neup-20251212.xsd (EX-101.SCH) — 3KB
• neup-20251212_lab.xml (EX-101.LAB) — 33KB
• neup-20251212_pre.xml (EX-101.PRE) — 22KB
• ea0270035-8k_neuphoria_htm.xml (XML) — 3KB

07. Submission

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 12, 2025, the Company held an Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the four proposals described below. The proposals presented at the Annual Meeting are described in detail in the Definitive Proxy Statement filed with the Securities and Exchange Commission on November 24, 2025. Of the 2,357,613 shares of Common Stock outstanding and entitled to vote at the Annual Meeting, 937,447, or 39.76%, of the outstanding and eligible shares, were present either in person or by proxy and entitled to vote on all proposals. Holders of Common Stock voted one vote per share on all matters properly brought before the Annual Meeting. The results for each of the proposals submitted to a vote of shareholders at the Annual Meeting are as follows: Proposal No. 1 – Election of two class I directors for a three-year term With respect to the proposal for the election of two Class I directors for a three year term, the voting with respect to Proposal 1 was as follows: Nominee For Withheld Peter Miles Davies 759,850 152,879 David Wilson 758,571 154,164 Stephen Doberstein 136,780 775,959 Kimberly Smith 136,740 775,997 Proposal No. 2 – Ratify the appointment of our auditor for the fiscal year ended June 30, 2026 With respect to the proposal to ratify the appointment of Wolf & Company P.C. as our independent registered public accounting firm for the fiscal year ending June 30, 2026, the voting with respect to Proposal 2 was as follows: For Against Abstain 807,022 96,245 34,180 1 Proposal No. 3 – Approve (on a non-binding advisory basis) the compensation of our named executive officers With respect to the proposal to approve (on a non-binding advisory basis) the compensation of our named executive officers, the voting with respect to Proposal 3 was as follows: For Against Abstain 726,184 154,109 32

SIGNATUREs

SIGNATUREs Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NEUPHORIA THERAPEUTICS INC. By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos Chief Executive Officer Date: December 17, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR